Company / SG&A per Share
ALNYLAM PHARMACEUTICALS, INC. SG&A per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$9.36
FY2025
5-year range
$4.11 / $9.36
FY2021-FY2025
Trend
+20.7%
vs FY2024
Sector context
#15 of 210
Health Care
What the data says
Among 210 Health Care companies, ALNYLAM PHARMACEUTICALS, INC. is in the bottom 7% for sg&a per share. SG&A per Share has increased for 7 consecutive years, from $0.90 in FY2018 to $9.36 in FY2025.
Based on SEC 10-K filings.
9.36 in FY2025 with a 5-year CAGR of +22.4%. Top quartile in the Health Care sector.
Increased from $6.42 to $9.36 over the past 2 years.
Health Care sector context is included.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- +24.1%
- 5-Year CAGR
- +22.4%
- 10-Year CAGR
- -
Sector benchmark
Bottom 7% in Health CareTop 93% of 210This company $9.36 Sector average $29.50
▼
-68.3% below sector average
Key checks
Key Insights
- ALNYLAM PHARMACEUTICALS, INC.'s sg&a per share has grown for 7 consecutive years.
- In FY2025, sg&a per share increased 20.7% year-over-year.
- Ranks #15 out of 210 companies in the Health Care sector.
- Lowest sg&a per share in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 0.37 (distress zone, below 1.8 threshold)
- Negative profit margin: -12.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $9.36 | +20.7% |
| FY2024 | $7.75 | +20.8% |
| FY2023 | $6.42 | +31.1% |
| FY2022 | $4.90 | +19.0% |
| FY2021 | $4.11 | +20.7% |
| FY2020 | $3.41 | +73.0% |
| FY2019 | $1.97 | +119.8% |
| FY2018 | $0.90 | -59.3% |
| FY2017 | $2.20 | +110.9% |
| FY2016 | $1.04 | +44.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026